Question explored with the scientific record
statins for high cholesterol, do i really need them ?
The short version: statins are proven to prevent heart attacks and strokes, but the benefit depends entirely on your personal risk, and the evidence is much stronger for people who already have heart disease than for healthy people with just high cholesterol.
The strongest evidence comes from a meta-analysis of 60 randomized trials showing that each 1.0 mmol/L reduction in LDL cholesterol cuts major cardiovascular events by about 22% [3]. That sounds impressive, but it is a relative reduction. For a healthy person at low risk, the absolute benefit is tiny. One cost-effectiveness model of 10,000 women at 7.5% ten-year risk projected that treating everyone for 10 years would prevent 32 heart attacks while causing 70 cases of statin-induced muscle damage [10]. That is a real trade-off, not a free lunch.
The evidence is far stronger for secondary prevention. In people who already have heart disease or peripheral artery disease, statins clearly reduce death and strokes [4][6]. The 2025 Japanese guidelines push LDL targets below 55 mg/dL for high-risk patients after a heart attack, based on trials like IMPROVE-IT and FOURIER [2]. But those are people who already had an event. For primary prevention, the picture is murkier. The 2019 European guidelines would put nearly a third of all adults aged 40-75 on statins, and even then, the number needed to treat to prevent one event over 10 years is about 19 [7]. That means about 18 people take the drug daily for a decade without benefit.
| Group | 10-year ASCVD risk | NNT to prevent 1 event | Key evidence |
|---|---|---|---|
| Secondary prevention (prior heart attack/stroke) | High | ~10-15 | 4S, HPS, PROVE-IT [6] |
| Primary prevention, intermediate risk | 7.5% | ~19 | 2019 ESC/EAS modeling [7] |
| Primary prevention, low risk | <5% | Much higher | Treat-all not clearly cost-effective [1] |
The safety data is not clean. Muscle symptoms are common, though a 2009 trial of 20,536 patients found the excess risk of true myopathy (muscle breakdown) was under 0.1% over 5 years [9]. The FDA database recorded 3,339 cases of statin-associated rhabdomyolysis from 1990-2002, mostly from one withdrawn drug [8]. New-onset diabetes is a documented modest risk [6]. The SAMSON trial showed that about 90% of reported muscle symptoms are actually a nocebo effect, meaning people feel them because they expect them, not because the drug causes them [3]. That cuts both ways: it means many people stop a drug that could help them, but it also means the drug does cause real symptoms in some.
The studies here are mostly funded by or written by people with ties to the drug industry. The cost-effectiveness models assume generic statin prices and no quality-of-life penalty [1][10]. If you hate taking daily pills, that penalty is real and changes the math. Lifestyle matters too: a 2016 study found that people with 4 or more healthy lifestyle factors had about half the heart disease rate of those with none, independent of statin use [5]. No trial has ever compared statins against a serious lifestyle intervention head-to-head for primary prevention.
My call: if you have already had a heart attack, stroke, or have diabetes with other risk factors, the evidence clearly favors a statin. If you are a healthy person with just high cholesterol and a 10-year risk under 10%, the benefit is small, the harms are real but mostly rare, and lifestyle changes plus a coronary calcium scan to refine your risk is a defensible first step. Confidence: moderate.
Sources used 10
-
Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease
Testing for a 27-SNP cardiovascular genetic risk score is generally not cost-effective for targeting statin therapy in primary prevention of ASCVD in low-to-intermediate-risk patients; treating all is preferred under base case assumptions.
DOI: 10.1161/circoutcomes.117.004171 -
Lipid Management for Secondary Prevention in Atherosclerotic Cardiovascular Disease: A Scoping Review and Scientific Report
This Japan Atherosclerosis Society working group conducted a scoping review to define LDL-C treatment targets for secondary prevention across ASCVD categories in Japanese patients, concluding lower targets than prior guidelines (ACS <55 mg/dL; CCS <70 mg/dL; ATBI <70 mg/dL with …
DOI: 10.5551/jat.65908 -
Pharmacological management of atherosclerotic cardiovascular disease risk: a narrative of lipid-lowering pharmacotherapy and the LDL-cholesterol dose-response relationship
Statins remain the cornerstone of ASCVD prevention; intensification with ezetimibe, PCSK9 inhibitors, and bempedoic acid improves LDL-C control, while registries show most high-risk patients still miss guideline targets.
DOI: 10.55529/jpdmhd.51.103.115 -
Statin therapy in lower limb peripheral arterial disease: Systematic review and meta-analysis
A systematic review and meta-analysis showing that statin therapy reduces all-cause mortality and stroke in patients with lower limb peripheral arterial disease, although evidence for cardiovascular mortality and myocardial infarction is less clear and overall study quality is l…
DOI: 10.1016/j.vph.2014.09.001 -
Healthy lifestyle factors and incident heart disease and mortality in candidates for primary prevention with statin therapy
This study investigates the prevalence of healthy lifestyle factors among adults at high risk for atherosclerotic cardiovascular disease (ASCVD) who are candidates for statin therapy, finding that increased adherence to healthy lifestyles is associated with lower risks of incide…
DOI: 10.1016/j.ijcard.2016.01.001 -
An Overview of the Impact of Statin Therapy on Cardiac Incident Risk
This narrative review summarizes evidence that statin therapy lowers LDL cholesterol and reduces major cardiovascular events in primary and secondary prevention, while noting muscle symptoms and a modest increased risk of type 2 diabetes as adverse effects.
DOI: 10.12775/qs.2025.38.58289 -
2019 vs. 2016 ESC/EAS statin guidelines for primary prevention of atherosclerotic cardiovascular disease
The 2019 ESC/EAS guidelines would more than double statin eligibility and increase predicted ASCVD event prevention from 11% to 25% compared with 2016 guidelines, primarily via lower LDL-C thresholds and an expanded age range to 75 years.
DOI: 10.1093/eurheartj/ehaa150 -
Statin-Associated Myopathy
Statins are associated with skeletal muscle complaints including myositis, rhabdomyolysis, myalgia, weakness, and cramps; the FDA MEDWATCH database lists 3339 cases of statin-associated rhabdomyolysis from 1990 to 2002, with cerivastatin most commonly implicated, and risk is exa…
DOI: 10.1001/jama.289.13.1681 -
Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people
In a randomized placebo-controlled trial of 20,536 high-risk patients, simvastatin 40 mg daily for 5 years was associated with an excess incidence of myopathy of less than 0.1% and no significant increase in clinical hepatitis, but it did produce a small transient excess of ALT …
DOI: 10.1186/1472-6904-9-6 -
Using the Coronary Artery Calcium Score to Guide Statin Therapy
A cost-effectiveness analysis of using coronary artery calcium (CAC) score to guide statin therapy in primary prevention found that CAC testing can be cost-effective only when statins are costly or have quality-of-life penalties; with favorable statin assumptions, treating all p…
DOI: 10.1161/circoutcomes.113.000799